EGFR and non-small cell lung carcinoma: This was a Chinese, multicenter, phase 2, randomized controlled trial comparing erlotinib with chemotherapy (cisplatin plus gemcitabine) in patients with resectable, EGFR-mutated, stage IIIA (N2) NSCLC.